Octreotide-modified liposomes containing daunorubicin and dihydroartemisinin for treatment of invasive breast cancer

References

• Otten JD, Broeders MJ, Fracheboud J, et al. Impressive time-related influence of the Dutch screening programme on breast cancer incidence and mortality, 1975–2006. Int J Cancer. 2008;123:1929–1934.
   PubMed Web of Science ®Google Scholar
• Walker G, Xenophontos M, Chen L, et al. Long-term efficacy and safety of exemestane in the treatment of breast cancer. Patient Prefer Adherence. 2013;7:245–258.
   PubMed Web of Science ®Google Scholar
• Shi Y, Zhao Y, Shao N, et al. Overexpression of microRNA-96-5p inhibits autophagy and apoptosis and enhances the proliferation, migration and invasiveness of human breast cancer cells. Oncol Lett. 2017;13:4402–4412.
   PubMed Web of Science ®Google Scholar
• Yang X, Shi L, Yi C, et al. MiR-210-3p inhibits the tumor growth and metastasis of bladder cancer via targeting fibroblast growth factor receptor-like 1. Am J Cancer Res. 2017;7:1738–1753.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA-Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Fei F, Zhang D, Yang Z, et al. The number of polyploid giant cancer cells and epithelial-mesenchymal transition-related proteins are associated with invasion and metastasis in human breast cancer. J Exp Clin Cancer Res. 2015;34:158.
   PubMed Web of Science ®Google Scholar
• Shapiro IM, Cheng AW, Flytzanis NC, et al. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet. 2011;7:e1002218.
   PubMed Web of Science ®Google Scholar
• Kim RK, Kaushik N, Suh Y, et al. Radiation driven epithelial-mesenchymal transition is mediated by Notch signaling in breast cancer. Oncotarget. 2016;7:53430–53442.
   PubMedGoogle Scholar
• Nieto MA. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol. 2011;27:347–376.
   PubMed Web of Science ®Google Scholar
• Eivazy P, Atyabi F, Jadidi-Niaragh F, et al. The impact of the codelivery of drug-siRNA by trimethyl chitosan nanoparticles on the efficacy of chemotherapy for metastatic breast cancer cell line (MDA-MB-231). Artif Cells Nanomed Biotechnol. 2017;45:889–896.
   PubMed Web of Science ®Google Scholar
• Bhowmik SK, Ramirez-Pena E, Arnold JM, et al. EMT-induced metabolite signature identifies poor clinical outcome. Oncotarget. 2015;6:42651–42660.
   PubMedGoogle Scholar
• Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010;29:4741–4751.
   PubMed Web of Science ®Google Scholar
• Huang RY, Guilford P, Thiery JP. Early events in cell adhesion and polarity during epithelial-mesenchymal transition. J Cell Sci. 2012;125:4417–4422.
   PubMed Web of Science ®Google Scholar
• Lin CY, Tsai PH, Kandaswami CC, et al. Matrix metalloproteinase-9 cooperates with transcription factor Snail to induce epithelial-mesenchymal transition. Cancer Sci. 2011;102:815–827.
   PubMed Web of Science ®Google Scholar
• Lo HW, Hsu SC, Xia W, et al. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res. 2007;67:9066–9076.
   PubMed Web of Science ®Google Scholar
• Sigurdsson V, Hilmarsdottir B, Sigmundsdottir H, et al. Endothelial induced EMT in breast epithelial cells with stem cell properties. PloS One. 2011;6:e23833.
   PubMed Web of Science ®Google Scholar
• Simeonova M, Ivanova G, Enchev V, et al. Physicochemical characterization and in vitro behavior of daunorubicin-loaded poly(butylcyanoacrylate) nanoparticles. Acta Biomater. 2009;5:2109–2121.
   PubMed Web of Science ®Google Scholar
• Lotfi K, Zackrisson AL, Peterson C. Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance. Cancer Lett. 2002;178:141–149.
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185–229.
   PubMed Web of Science ®Google Scholar
• Singh NP, Lai H. Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci. 2001;70:49–56.
   PubMed Web of Science ®Google Scholar
• Zhang S, Ma Y, Jiang J, et al. Inhibition of urokinase-type plasminogen activator expression by dihydroartemisinin in breast cancer cells. Oncol Lett. 2014;7:1375–1380.
   PubMed Web of Science ®Google Scholar
• Hwang YP, Yun HJ, Kim HG, et al. Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via inhibition of PKCalpha/Raf/MAPKs and NF-kappaB/AP-1-dependent mechanisms. Biochem Pharmacol. 2010;79:1714–1726.
   PubMed Web of Science ®Google Scholar
• Li X, Zhou Y, Liu Y, et al. Preclinical efficacy and safety assessment of artemisinin-chemotherapeutic agent conjugates for ovarian cancer. EBioMedicine. 2016;14:44–54.
   PubMed Web of Science ®Google Scholar
• Zhang HY, Xu WQ, Wang YW, et al. Tumor targeted delivery of octreotide-periplogenin conjugate: synthesis, in vitro and in vivo evaluation. Int J Pharm. 2016;502:98–106.
   PubMed Web of Science ®Google Scholar
• Zhang J, Jin W, Wang X, et al. A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models. Mol Pharm. 2010;7:1159–1168.
   PubMed Web of Science ®Google Scholar
• Li XT, Ju RJ, Li XY, et al. Multifunctional targeting daunorubicin plus quinacrine liposomes, modified by wheat germ agglutinin and tamoxifen, for treating brain glioma and glioma stem cells. Oncotarget. 2014;5:6497–6511.
   PubMed Web of Science ®Google Scholar
• Ju RJ, Zeng F, Liu L, et al. Destruction of vasculogenic mimicry channels by targeting epirubicin plus celecoxib liposomes in treatment of brain glioma. Int J Nanomed. 2016;11:1131–1146.
   PubMed Web of Science ®Google Scholar
• Ying X, Wen H, Lu WL, et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release. 2010;141:183–192.
   PubMed Web of Science ®Google Scholar
• Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. JCO. 2006;24:2137–2150.
   PubMed Web of Science ®Google Scholar
• Tran TH, Nguyen AN, Kim JO, et al. Enhancing activity of artesunate against breast cancer cells via induced-apoptosis pathway by loading into lipid carriers. Artif Cells Nanomed Biotechnol. 2016;44:1979–1987.
   PubMed Web of Science ®Google Scholar
• Choi HJ, Park JH, Park M, et al. UTX inhibits EMT-induced breast CSC properties by epigenetic repression of EMT genes in cooperation with LSD1 and HDAC1. EMBO Rep. 2015;16:1288–1298.
   PubMed Web of Science ®Google Scholar
• Martin-Belmonte F, Perez-Moreno M. Epithelial cell polarity, stem cells and cancer. Nat Rev Cancer. 2011;12:23–38.
   PubMed Web of Science ®Google Scholar
• Renner G, Noulet F, Mercier MC, et al. Expression/activation of alpha5beta1 integrin is linked to the beta-catenin signaling pathway to drive migration in glioma cells. Oncotarget. 2016;7:62194–62207.
   PubMedGoogle Scholar
• Maschler S, Gebeshuber CA, Wiedemann EM, et al. Annexin A1 attenuates EMT and metastatic potential in breast cancer. EMBO Mol Med. 2010;2:401–414.
   PubMed Web of Science ®Google Scholar
• Zheng S, Jia Q, Shen H, et al. Treatment with the herbal formula Songyou Yin inhibits epithelial-mesenchymal transition in hepatocellular carcinoma through downregulation of TGF-beta1 expression and inhibition of the SMAD2/3 signaling pathway. Oncol Lett. 2017;13:2309–2315.
   PubMed Web of Science ®Google Scholar
• Mahmood MQ, Reid D, Ward C, et al. Transforming growth factor (TGF) beta1 and Smad signalling pathways: a likely key to EMT-associated COPD pathogenesis. Respirology. 2017;22:133–140.
   PubMed Web of Science ®Google Scholar
• Lakhani HA, de Mel A, Seifalian AM. The effect of TGF-beta1 and BMP-4 on bone marrow-derived stem cell morphology on a novel bioabsorbable nanocomposite material. Artif Cells Nanomed Biotechnol. 2015;43:230–234.
   PubMed Web of Science ®Google Scholar
• Roskoski R Jr. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas. Pharmacol Res. 2017;120:116–132.
   PubMed Web of Science ®Google Scholar
• Sharifpanah F, Behr S, Wartenberg M, et al. Mechanical strain stimulates vasculogenesis and expression of angiogenesis guidance molecules of embryonic stem cells through elevation of intracellular calcium, reactive oxygen species and nitric oxide generation. BBA-Mol Cell Res. 2016;1863:3096–3105.
   PubMed Web of Science ®Google Scholar
• Baker GJ, Yadav VN, Motsch S, et al. Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. Neoplasia. 2014;16:543–561.
   PubMed Web of Science ®Google Scholar
• Jun-Jiang C, Huan-Jiu X. Vascular endothelial growth factor 165-transfected adipose-derived mesenchymal stem cells promote vascularization-assisted fat transplantation. Artif Cells Nanomed Biotechnol. 2016;44:1141–1149.
   PubMed Web of Science ®Google Scholar
• Cesi V, Casciati A, Sesti F, et al. TGFbeta-induced c-Myb affects the expression of EMT-associated genes and promotes invasion of ER + breast cancer cells. Cell Cycle. 2011;10:4149–4161.
   PubMed Web of Science ®Google Scholar
• Canel M, Serrels A, Frame MC, et al. E-cadherin-integrin crosstalk in cancer invasion and metastasis. J Cell Sci. 2013;126:393–401.
   PubMed Web of Science ®Google Scholar
• Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17:548–558.
   PubMed Web of Science ®Google Scholar
• Ihara Y, Inai Y, Ikezaki M. Alteration of integrin-dependent adhesion and signaling in EMT-like MDCK cells established through overexpression of calreticulin. J Cell Biochem. 2011;112:2518–2528.
   PubMed Web of Science ®Google Scholar
• Musial K, Bargenda A, Zwolinska D. Urine survivin, E-cadherin and matrix metalloproteinases as novel biomarkers in children with chronic kidney disease. Biomarkers. 2015;20:177–182.
   PubMed Web of Science ®Google Scholar